Why Novocure Stock Skyrocketed Today

Joe Tenebruso, The Motley Fool
·2 min read
Why Novocure Stock Skyrocketed Today

Shares of Novocure (NASDAQ: NVCR) soared nearly 50% on Tuesday after the oncology company provided an update on a phase 3 trial of its experimental lung cancer treatment. An independent data monitoring committee (DMC) informed Novocure that an interim analysis for the study would be accelerated after data from 210 patients showed no evidence of increased systemic toxicity. The study is designed to evaluate Novocure's Tumor Treating Fields, or TTFields, which are electric fields that could potentially disrupt cancer cell division while leaving healthy cells largely unaffected.